Roche Holding AG

Diagnostics revenues are inherently recurring through analyzer-committed reagent contracts, while pharmaceutical revenues benefit from high clinical inertia in cancer, MS, and hemophilia treatment. Forward visibility is moderated by a biosimilar wave, with Roche guiding to roughly CHF 1 billion in loss-of-exclusivity impact in FY2026.

Roche spans two structurally distinct divisions with different demand drivers: Pharmaceuticals (approximately 70% of revenues) and Diagnostics (approximately 30%). Within Pharmaceuticals, revenues concentrate in oncology and specialty biologics, limiting diversification across truly uncorrelated end markets.

Revenue is distributed across the US, Europe, and international markets, with Switzerland a negligible home-market share. China, historically a mid-single-digit percentage of group sales, saw revenues decline 23-26% in the first half of 2025 due to volume-based procurement pricing reforms, a meaningful headwind but not a dominant concentration.

Core operating profit grew 13% at constant exchange rates on 7% sales growth in FY2025, demonstrating structural operating leverage in the pharmaceuticals business. The diagnostics division carries more linear cost dynamics from manufacturing and instrument service, partially offsetting group-level scale benefits.

Diagnostics revenues are genuinely recurring through multi-year reagent agreements tied to the installed instrument base. Pharmaceutical revenues are mission-critical for patients with cancer, MS, or hemophilia, where discontinuing treatment carries severe health consequences, making this revenue substantially non-discretionary even if not contractually recurring.